KIG
BMRN icon

Kowal Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kowal Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$15K – 227
2021
Q3 		$15K Buy
+200
New +$15.8K ﹤0.01% 431

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kowal Investment Group's BMRN Position: Q4 2021 in Review

Kowal Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 200 shares — an estimated $15K sold.

Kowal Investment Group first reported a position in BMRN in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Kowal Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kowal Investment Group sold 200 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $15K.
  • Kowal Investment Group first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kowal Investment Group's BioMarin Pharmaceuticals position peaked at $15K in Q3 2021.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.